智通财经APP获悉，和誉-B(02256)尾盘涨超4%，截至发稿，涨3.78%，报8.24港元，成交额23268.13万港元。
消息面上，和誉近期连续回购。5月14日，公司再次斥资275.6万港元回购34.7万股。平安证券指出，2024年和誉首次实现全年盈利，2025年公司启动不超过2亿港元新一轮的股票回购计划，进一步提升股东价值，同时再次彰显出管理团队对公司未来发展前景的坚定信心。
海通国际发布研报称，2024年，和誉全年营收为5.04亿元，同比增超25倍，营收的增加主要来自于与默克达成Pimicotinib（CSF-1R）大中华区授权协议，首付款7000万美元以及艾力斯的100万美元里程碑收入。净利润达2830万元。公司目前现金储备充沛，截至2024年12月31日，现金及银行结余19.6亿元。公司在2024年首次实现年度盈利。2025年，公司核心管线匹米替尼有望递交全球NDA，商业化在即。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.